MARKET

CVAC

CVAC

Curevac B.V.
NASDAQ
4.140
+0.240
+6.15%
Opening 15:52 05/22 EDT
OPEN
3.920
PREV CLOSE
3.900
HIGH
4.160
LOW
3.870
VOLUME
655.64K
TURNOVER
--
52 WEEK HIGH
5.28
52 WEEK LOW
2.370
MARKET CAP
932.15M
P/E (TTM)
4.772
1D
5D
1M
3M
1Y
5Y
1D
CureVac price target lowered to $2 from $2.50 at BofA
TipRanks · 1d ago
Bank of America Securities Sticks to Their Sell Rating for CureVac (CVAC)
TipRanks · 1d ago
CureVac N.V. Reports Q1 2025 Financial Results Amid Strategic Restructuring
TipRanks · 1d ago
CureVac Reports Q1 2025 Financial Results Amid Revenue Decline
TipRanks · 1d ago
CureVac Reports Q1 2025 Financials and Advances in Oncology Pipeline
TipRanks · 1d ago
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction
Benzinga · 2d ago
CureVac Q1 Sales $946.45K Miss $3.34M Estimate, Company Exits Quarter With Cash And Equivalents Worth $460.91M
Benzinga · 2d ago
CureVac BV reports Q1 results
Seeking Alpha · 2d ago
More
About CVAC
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

Webull offers CureVac BV stock information, including NASDAQ: CVAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVAC stock methods without spending real money on the virtual paper trading platform.